Inogen stock faces a strategic reset after rental sale
Inogen has agreed to sell its U.S. oxygen rental business to Rotech Healthcare for up to $25 million, a strategic divestiture aimed at improving business mix and profitability. The rental unit generated $24.3 million in revenue in the first half of 2026 and will be reported as discontinued operations from Q3 2026. Needham maintains a Buy rating and a $12.00 price target on Inogen stock, suggesting significant upside from its current price after the announced sale.
Inogen sharpens business focus with $25m oxygen rental unit divestment
Inogen has agreed to sell its US oxygen rental business to Rotech Healthcare for up to $25 million to refine its focus on product innovation. The deal, expected to close by Q4 2026, includes a long-term supply agreement with Rotech to expand access to Inogen's oxygen concentrators. This strategic move follows declining revenues in the rental segment and aims to strengthen Inogen's business and financial profile amidst rising COPD cases.
Inogen to sell U.S. oxygen rental business to Rotech for $25M
Inogen Inc. announced an agreement to sell its U.S. oxygen rental business to Rotech Healthcare for up to $25 million in cash, with the transaction expected to close in the fourth quarter of 2026. Following the divestiture, Inogen will concentrate on respiratory innovation and partner with home medical equipment providers for distribution, while also increasing its share repurchase authorization by $15 million to a total of $45 million. This strategic move aims to strengthen Inogen's business and financial profile, allowing it to focus on core innovation.
Inogen to sell U.S. oxygen rental business to Rotech for $25M
Inogen Inc. announced its plan to sell its U.S. oxygen rental business to Rotech Healthcare for up to $25 million in cash, with the transaction expected to close in Q4 2026. This divestiture will allow Inogen to concentrate on respiratory innovation and partner with home medical equipment providers for distribution, while also maintaining its direct-to-consumer sales channel. The company's Board of Directors approved a $15 million increase to its share repurchase authorization, bringing the total to $45 million, set to expire on June 30, 2028.
Inogen plans to sell its oxygen rentals to Rotech; patients can still buy its products directly.
Inogen has announced the divestiture of its U.S. oxygen rental business to Rotech Healthcare for an estimated cash consideration of up to $25 million. This strategic move aims to streamline Inogen's business model, focusing on higher revenue growth and adjusted operating income, while partnering with home medical equipment providers to expand product access. Inogen will also enter a long-term supply agreement with Rotech and intends to present the rental business as discontinued operations starting in Q3 2026, with an increased share repurchase authorization of $15 million.
Inogen to Sell U.S. Oxygen Rental Assets to Rotech Healthcare for Up to $24.8 Million
Inogen has entered into an Asset Purchase Agreement to sell its U.S. oxygen rental business assets to Rotech Healthcare for an estimated $24.8 million. The payment will be made in six installments and is subject to post-closing reconciliation. This transaction, which includes inventory and patient records, aims to streamline Inogen's portfolio and is subject to customary closing conditions.
Inogen Announces Divestiture of Its U.S. Oxygen Rental Business to Rotech
Inogen, Inc. announced its divestiture of its U.S. oxygen rental business to Rotech Healthcare for up to $25 million and signed a new long-term supply agreement with Rotech. This strategic move aims to streamline Inogen's commercial model, drive higher revenue growth, and improve adjusted operating income. The transaction is expected to close in Q4 2026, and Inogen's Board has approved a $15 million increase to its share repurchase authorization.
Trading the Move, Not the Narrative: (INGN) Edition
This article analyzes Inogen Inc (NASDAQ: INGN), noting a near-term neutral sentiment suggesting a pause in its mid and long-term weakness. It highlights an exceptional 75.0:1 risk-reward setup targeting a 15.3% gain against a 0.2% risk, and provides three AI-generated trading strategies for different risk profiles. The strategies include position trading, momentum breakout, and risk hedging, with specific entry, target, and stop-loss zones.
Inogen Portable Oxygen Concentrator(s) Review 2026
This article reviews Inogen's portable oxygen concentrators for 2026, focusing on the Inogen Rove 4 and Rove 6 models. It highlights their lightweight design, FAA approval for air travel, battery life, and pulse-dose delivery system, noting that they may not be suitable for those needing continuous-flow oxygen. The review also covers pricing, pros and cons of each model, and customer feedback.
Inogen stock trades as Nasdaq reaches a new high
Inogen stock (INGN) is trading against a new record high set by the Nasdaq Composite on September 23, 2026. While the strong growth-stock environment can influence trading, the article emphasizes that Inogen's operating figures, such as revenue and earnings, remain the primary factors for assessing the medical-device company's performance. Investors should focus on company-specific data and compare current results to prior-year periods for a true measure of progress.
Inogen Inc (NASDAQ: INGN) Grants 1,500 Shares to Chief Accounting Officer Mary E Wright at $5.33 Each
Inogen Inc. (NASDAQ: INGN) has granted 1,500 shares to its Chief Accounting Officer, Mary E Wright, at a price of $5.33 per share. This transaction, executed on September 1, 2026, under code A, increases her total ownership in the company to 20,629 shares. The disclosure provides transparency into her ownership stake and the details of the equity award.
Inogen (INGN) accounting chief adds 1,500 shares in stock purchase
Inogen's Vice President and Chief Accounting Officer, Mary E. Wright, acquired 1,500 shares of the company's common stock on September 1, 2026, through its 2014 Employee Stock Purchase Plan. This purchase increased her direct holdings to 20,629 shares. The acquisition was made at a price of $5.33 per share.
Inogen, Inc. (NASDAQ:INGN) Released Earnings Last Week And Analysts Lifted Their Price Target To US$12.67
Following Inogen's recent earnings report, analysts have significantly increased their price targets for the company, now averaging US$12.67 per share. This upgrade reflects a more optimistic outlook from the market, with the consensus price target rising by 21% from previous estimates. Despite the positive analyst sentiment, the article highlights that the stock has experienced a 21% decline over the past week.
Here's Why You Should Retain Inogen Stock in Your Portfolio for Now
Inogen, Inc. (INGN) is positioned for growth due to strong demand for portable oxygen concentrators (POCs), an expanding B2B market, and international expansion. Despite these positive indicators, the company faces risks such as U.S. revenue pressure from channel shifts, volatility due to international distributor inventory timing, and clinical/reimbursement challenges for its Simeox technology. Inogen's valuation appears attractive with a P/S ratio of 0.4 compared to the industry's 2.7, and analysts project continued business improvements.
Top 3 Health Care Stocks That Could Blast Off This Month
This article identifies three oversold healthcare stocks—Veracyte Inc (VCYT), Akso Health Group (AHG), and Inogen Inc (INGN)—that could present buying opportunities. These companies have a Relative Strength Index (RSI) near or below 30, indicating they may be undervalued. Recent news affecting each company, including earnings and R&D initiatives, are highlighted.
CPAP Store USA Adds New Inogen Aurora CPAP Mask Line
CPAP Store USA has launched Inogen's new Aurora CPAP Mask Collection, becoming the first authorized online and in-store retailer for these non-magnetic masks. This expansion introduces three mask interfaces—F1 Full Face, N1 Nasal, and P1 Nasal Pillows—offering greater choice and comfort for CPAP and BiPAP users. The move signifies a notable expansion for both companies, with Inogen entering sleep therapy and CPAP Store USA broadening its respiratory care offerings.
Inogen, Inc. (NASDAQ:INGN) Released Earnings Last Week And Analysts Lifted Their Price Target To US$12.67
Inogen, Inc. (NASDAQ:INGN) reported quarterly results last week, showing revenues of US$95m and losses of US$0.14 per share, which were better than analyst expectations. Following the earnings, analysts maintained their loss per share estimates for 2026 but downgraded revenue forecasts, expecting Inogen to grow slower than the broader industry. Despite the revenue downgrade, analysts lifted their price target for Inogen by 8.6% to US$12.67 per share, suggesting an improvement in the company's intrinsic value.
Dimensional Fund Advisors LP Reduces Position in Inogen, Inc $INGN
Dimensional Fund Advisors LP significantly reduced its stake in Inogen, Inc. by 28.3% in the first quarter, selling over 200,000 shares but still retaining a substantial holding. Despite this reduction, other institutional investors have increased their positions, and Inogen's stock holds a "Moderate Buy" consensus rating from analysts, even after a reiterated "sell" rating from Weiss Ratings. The company recently reported a narrower-than-expected quarterly loss, though revenue slightly missed forecasts, with analysts anticipating a full-year loss of $0.77 per share.
Inogen Cuts 2026 Revenue Outlook as U.S. Channel Pressure Persists
Inogen, Inc. (INGN) has lowered its 2026 revenue outlook due to persistent U.S. channel pressure, specifically a decline in direct sales and rentals, despite strong international growth and improved profitability. The company expects 2026 revenues to be between $355 million and $361 million, a reduction from previous estimates. Inogen is focusing on business-to-business efforts and new products like the Voxi stationary oxygen concentrator to adapt to the changing market.
Inogen Cuts 2026 Revenue Outlook as U.S. Channel Pressure Persists
Inogen, Inc. (INGN) has lowered its 2026 revenue outlook due to persistent U.S. channel pressure, despite experiencing better profitability and international growth in the second quarter. The company is facing a shift in the U.S. oxygen market towards portable oxygen concentrators as initial therapy, impacting its direct-to-consumer sales, while international sales continue to grow. Inogen is expanding its business-to-business efforts and new product offerings like Voxi stationary oxygen concentrators and Aurora CPAP masks to offset these challenges.
Should Investors Buy Inogen as Low Valuation Meets Execution Risk?
Inogen (INGN) trades at a significant discount compared to its industry peers, driven by improved Q2 2026 margins and strong international demand. While the company boasts a debt-free balance sheet and expanding respiratory offerings, persistent weakness in U.S. direct sales and rentals presents execution risks. The current low valuation combined with mixed operational signals suggests a cautious "hold" stance for investors.
Inogen Launches First CPAP Mask Portfolio
Inogen Inc. has launched its Aurora CPAP mask portfolio in the United States, marking its entry into the obstructive sleep apnea market. This expansion aims to leverage existing distribution channels to offer a variety of mask designs—F1 Full Face, N1 Nasal Cushion, and P1 Nasal Pillows—to meet diverse patient needs. The company reports high patient satisfaction with the comfort and performance of the new masks, which are seen as a key growth catalyst in Inogen's strategy to become a broader home healthcare respiratory solutions provider.
Inogen Launches Voxi 5 Stationary Oxygen Concentrator
Inogen Inc. has launched the Voxi 5, a new stationary oxygen concentrator (SOC) developed with Yuwell Medical, to expand access to oxygen therapy for long-term care patients in the US. This device provides 1-5 liters per minute of continuous flow oxygen, offering a compact and mobile solution designed for affordability and to complement Inogen's portable oxygen concentrator line. The Voxi 5 aims to serve price-sensitive customers and those needing additional units for multi-room use, reinforcing Inogen's commitment to accessible respiratory care.
Inogen Q2 Earnings Beat Estimates, Sales Rise Y/Y, 2026 View Cut
Inogen reported breakeven earnings for Q2 2026, beating estimates, with revenues of $95.1 million, up 3% year over year, driven by strong international demand and new products. However, the company cut its full-year 2026 revenue guidance to $355-$361 million due to continued U.S. sales channel mix pressure. Despite this, Inogen is focused on expanding its respiratory care portfolio and expects to launch at least one new product annually.
Inogen Q2 Earnings Beat Estimates, Sales Rise Y/Y, 2026 View Cut
Inogen (INGN) reported breakeven earnings for Q2 2026, surpassing estimates, with revenues rising 3% year-over-year to $95.1 million, driven by strong international demand and new products. Despite this, the company cut its full-year 2026 revenue guidance to $355-$361 million, down from previous estimates, due to continued U.S. sales channel mix pressure and timing of international distributor purchases. The company continues to focus on expanding its respiratory care portfolio and international presence.
Inogen, Inc. (NASDAQ:INGN) Released Earnings Last Week And Analysts Lifted Their Price Target To US$12.67
Following Inogen, Inc.'s recent earnings report, analysts reconfirmed their loss per share estimates but downgraded revenue forecasts for 2026, predicting slower growth than the broader industry. Despite this, the consensus price target was lifted to US$12.67, suggesting analysts see an improvement in the company's intrinsic value.
Inogen, Inc. (NASDAQ:INGN) Released Earnings Last Week And Analysts Lifted Their Price Target To US$12.67
Inogen, Inc. (NASDAQ:INGN) reported quarterly results last week, with revenues of US$95m matching predictions and statutory losses coming in 8.7% smaller than expected at US$0.14 per share. Following the report, analysts reconfirmed their loss per share estimates for next year but downgraded revenue estimates, forecasting slower growth than the broader industry. Despite the revenue downgrade, analysts increased their price target by 8.6% to US$12.67 per share, suggesting an improvement in the company's intrinsic value.
Arrowstreet Capital Limited Partnership Acquires 393,310 Shares of Inogen, Inc $INGN
Arrowstreet Capital Limited Partnership significantly increased its stake in Inogen, Inc. by 203.9% in the first quarter, purchasing 393,310 additional shares, bringing its total holdings to 586,159 shares. This makes Arrowstreet Capital own 2.16% of the medical technology company, with institutional investors collectively holding 89.94% of the stock. Despite a recent quarterly loss per share, Inogen's revenue exceeded expectations, and the stock currently holds a "Moderate Buy" consensus rating from analysts.
Inogen (NASDAQ:INGN) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS
Inogen (NASDAQ:INGN) reported quarterly earnings, beating expectations with a loss of $0.14 per share against a projected $0.15 loss. While revenue slightly missed estimates at $95.08 million, the company showed improved profitability with a 15% rise in adjusted EBITDA and strong international sales growth. Despite reducing full-year revenue guidance due to U.S. direct-channel pressures, Inogen increased its full-year adjusted EBITDA outlook, driven by new product traction and international expansion.
Inogen (INGN) Has a New Rating from B. Riley Securities
B. Riley Securities initiated coverage on Inogen (INGN) with a Buy rating and a $14.00 price target, following Needham's Buy rating and $12.00 price target for the stock. Inogen reported a quarterly revenue of $95.08 million and a GAAP net loss of $3.85 million for the quarter ending June 30, showing improved financial performance compared to the previous year. This article includes syndicated content and notes that The Globe and Mail has not reviewed or endorsed it.
Inogen Inc Q2 2026: Revenue $95.08M, EPS $(0.14) — 10-Q Summary
Inogen Inc. reported Q2 2026 revenue of $95.08M and diluted EPS of $(0.14), marking modest top-line growth and improved margins. The company's net loss narrowed to $3.85M from $4.15M a year prior, driven by higher unit volumes and favorable foreign exchange, particularly in international sales. Gross margin also improved to 46.2% due to manufacturing leverage and lower chip premium costs.
Inogen, Inc. (INGN) Stock Price, News, Quote & History
This Yahoo Finance page provides detailed financial information for Inogen, Inc. (INGN), a medical technology company specializing in respiratory health products. It includes real-time stock quotes, historical data, key financial metrics, performance overview, earnings trends, analyst insights, and comparison tools with similar companies in the medical devices industry.
Inogen Inc (INGN) (Q2 2026) Earnings Call Highlights: Strong International Growth and New ...
Inogen Inc. (INGN) reported strong international revenue growth of 15% year-over-year and core POC unit volume growth of over 12% in Q2 2026, with new products Voxy and Aurora gaining traction. Despite these positive indicators and an expanded gross margin, the company lowered its full-year 2026 revenue guidance due to declining U.S. sales and rental revenue, reflecting channel mix challenges and a structural market shift. Inogen maintains a strong balance sheet and increased its adjusted EBITDA guidance, while actively addressing the U.S. market headwinds and exploring new product opportunities.
Inogen (INGN) Reports Q2 Loss, Tops Revenue Estimates
Inogen (INGN) reported a Q2 loss of $0.14 per share, which was better than the Zacks Consensus Estimate of a $0.17 loss, and also surpassed revenue estimates with $95.08 million. Despite underperforming the S&P 500 year-to-date, the company's stock currently holds a Zacks Rank #3 (Hold), indicating an expected performance in line with the market. Investors are advised to monitor management's commentary and future estimate revisions.
Inogen Inc earnings beat by $0.03, revenue topped estimates
Inogen Inc (NASDAQ: INGN) reported its second-quarter earnings, beating analyst EPS estimates by $0.03 with an EPS of $-0.14. The company also surpassed revenue expectations, bringing in $95.1M against a consensus estimate of $95.05M. Despite the beat, the stock has seen a -7.83% decline in the last three months, though it is up 10.22% over the last year, with its financial health rated as "good performance" by InvestingPro.
Inogen, Inc Revenue Breakdown – NASDAQ:INGN
Inogen, Inc. (NASDAQ: INGN) generated $348.67 million USD in revenue last year. The primary driver of this revenue was the Oxygen Concentrators and Related Accessories segment, contributing $295.30 million USD. Geographically, the United States was the largest contributor to the company's revenue, accounting for $209.84 million USD.
Inogen Inc (INGN) Cash Flow
This article provides a detailed cash flow statement for Inogen Inc (INGN), outlining quarterly and annual data for operating, investing, and financing activities. It includes key financial metrics such as net income, capital expenditures, and free cash flow, along with year-over-year percentage changes. The article also features an FAQ section explaining various cash flow components and their significance for investors.
INGN|Inogen Inc|Price:6.405|Chg%:+0.255
This article provides a detailed company profile for Inogen Inc (INGN), a medical technology company specializing in respiratory products like portable oxygen concentrators. It covers the company's background, business scope, key products such as the Inogen One and Inogen Rove systems, and executive information. The article also touches on market performance, shareholder details, and institutional holdings.
INGN|Inogen Inc|Price:6.150|Chg%:-0.170
This article provides a detailed financial overview of Inogen Inc. (INGN), including its stock performance, key financial indicators like EPS, revenue, and net profit from quarterly and annual reports, and a summary of balance sheet and cash flow statements. It highlights the company's latest earnings date, EPS and revenue forecasts, and an "Analyst Rating" of BUY.
Inogen Inc (INGN) Income Statement
This article provides a detailed quarterly and annual income statement for Inogen Inc (INGN), outlining key financial metrics such as total revenue, cost of revenue, operating expenses, and net income. It also includes an FAQ section to help users understand how to interpret these financial statements and identifies important metrics for analyzing INGN stock. The data covers financial periods from FY2012Q3 through FY2026Q1, highlighting trends in the company's financial performance.
Inogen Inc (INGN) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis for Inogen Inc (INGN), detailing its current valuation score, market capitalization, and P/E ratio. As of July 24, 2026, the company's valuation score is 8.91, placing it 58th in the Healthcare Equipment & Supplies industry. The article notes that several key valuation metrics like P/B, P/S, and P/CF have not been disclosed by the company yet.
Inogen Inc (INGN) Institutional Confidence
Inogen Inc (INGN) has an institutional shareholding score of 7.00, placing it 79th in the Healthcare Equipment & Supplies industry. Institutional investors hold 75.89% of shares, a 4.39% increase quarter-over-quarter. Steven Cohen is the largest institutional shareholder, with 2.35% of outstanding shares.
INGN|Inogen Inc|Price:6.310|Chg%:+0.160
This article provides a comprehensive stock analysis of Inogen Inc (INGN), highlighting its relatively healthy fundamentals, high growth potential, and current valuation as "fairly valued" within the Healthcare Equipment & Supplies industry. Despite recent weak stock market performance, the company exhibits strong fundamentals and high institutional ownership. Analysts have rated it as a "Buy" with a target price of $12.00, suggesting the stock price is expected to remain stable in the medium term.
Inogen to report Q2 2026 results after market close, host conference call
Inogen (NASDAQ: INGN) has scheduled the release of its second-quarter 2026 financial results for August 6, 2026, after the market closes. The company will also host an earnings call on the same day at 2 p.m. PT (5 p.m. ET), with a webcast available through its investor relations website. This announcement was created using generative AI based on content originally published by Inogen via Business Wire.
Inogen to report second quarter 2026 results on August 6
Inogen will release its second quarter 2026 financial results after market close on Thursday, August 6, 2026. The medical technology company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET to discuss its performance. Investors can access the live webcast or a replay, which will be available until August 13, 2026.
Press Release: Inogen to Report Second Quarter 2026 Financial Results on August 6, 2026
Inogen is scheduled to report its second-quarter 2026 financial results on August 6, 2026, after the market closes. The company will also hold a conference call and live webcast to discuss these results on the same day. Investors can access the webcast or dial into the call for participation.
Inogen (INGN) Stifel 2024 Healthcare Conference Summary
Inogen (INGN) shared a summary of their Stifel 2024 Healthcare Conference, detailing efforts in leadership and culture transformation under new CEO and CFO focused on growth, profitability, and innovation. The company is rebaselining its DTC business for profitability, scrutinizing costs, and enhancing B2B channel growth through improved relationships and digital health initiatives. All channels are being optimized for profitability, with improved DTC profitability expected in the latter half of the next year.
Form 4 Inogen Inc For: 9 July By Investing.com
This article reports on a Form 4 filing for Inogen Inc (IGN) relating to transactions on July 9, 2026. The brief piece indicates that Inogen Inc. has a stock symbol INGN and includes its current performance at the time of publication. The content primarily serves as a notification of a regulatory filing.
Inogen (INGN) EVP, COO awarded 130,000 restricted stock units vesting from 2026
Inogen Inc.'s EVP and COO, Andrew P. Reding, has been granted 130,000 restricted stock units (RSUs). These RSUs will begin vesting on September 1, 2026, with one-third vesting after one year and the remaining units vesting in equal annual installments, contingent on his continued employment. This equity award aims to align the executive's compensation with the company's long-term performance.
Form 4 Inogen Inc For: 9 July By Investing.com
This article from Investing.com reports on a Form 4 filing for Inogen Inc. on July 9th. Form 4 filings disclose changes in beneficial ownership of securities, often indicating insider trading by company officers, directors, or significant shareholders. The article is very brief and seems to be a placeholder for a more detailed report on the specific transactions.
